亚太药业控股权过户完成 实际控制人变更为邱中勋

Group 1 - Zhejiang Apac Pharmaceutical Co., Ltd. announced the completion of the transfer of control to Xinghao Holdings, marking the end of a three-month control change process [1] - The transfer involved a share transfer at a price of 8.26 yuan per share, totaling 900 million yuan for a 14.61% stake, representing a 45.68% premium over the pre-suspension price of 5.67 yuan [1] - Apac Pharmaceutical plans to raise up to 700 million yuan through a private placement to fund new drug research and development, further consolidating Xinghao Holdings' control [1] Group 2 - Xinghao Holdings has signed a technology development contract with Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. for the domestic rights transfer of the innovative drug STC008, targeting late-stage non-small cell lung cancer [2] - The change in control signifies a new era for Apac Pharmaceutical under the leadership of Qiu Zhongxun, who is expected to integrate digital ecosystems with the company's R&D capabilities [2] - The market anticipates that Qiu Zhongxun will lead the revival and new achievements of this established pharmaceutical company [2]